Descriptive Analysis of Acceptance by Prescribers and Economic Benefit of Pharmacist Recommended Interventions in a Critical Care Unit by Lee, YoonJung & Gettman, Lana
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                       2018, Vol. 9, No. 2, Article 15                     INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v9i2.958  
1 
 
Descriptive Analysis of Acceptance by Prescribers and Economic Benefit of Pharmacist 
Recommended Interventions in a Critical Care Unit 
YoonJung Lee, PharmD1, 2; Lana Gettman, PharmD2 
1Texas Tech University Health Sciences Center; 2Harding University College of Pharmacy 
 
 
ABSTRACT  
Background: Pharmacist clinical intervention is defined as the action that identifies and prevents medication-related problems and 
optimizes patient’s medication therapy in cooperation with other healthcare professionals. Types of clinical interventions may vary, 
but each is patient specific. Few studies have focused on clinical pharmacists interventions in a critical care setting at a rural hospital. 
Objectives: The purpose of this study was to assess physician acceptance rate of pharmacist-recommended interventions in the 
critical care unit (CCU) at a rural hospital over five years and to evaluate the economic benefit of accepted pharmacist-recommended 
interventions over a one-year time period.  
Methods: This study was a retrospective chart review over a five-year time period. Each intervention was categorized and analyzed 
for acceptance or non-acceptance by the treating physician. Evaluation of economic benefit, cost saving and cost avoidance, for a 
one-year time period was performed.  
Results: A total of 1275 interventions were documented during study period. The average acceptance rate for documented 
interventions was 56%. The acceptance rate by physicians increased over the study period; with the acceptance rate in 2013 being 
statistically significantly higher than any other years. The overall cost saving for selected interventions was $432 for the one year. The 
overall cost avoidance of all accepted interventions for the one year was $453,339.36-$468,327.62. 
Conclusion: Clinical pharmacists provide various types of interventions to improve patient care. The analysis of potential cost saving 
and cost avoidance of selected interventions illustrated a positive economic outcome.  
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Introduction 
Pharmacist clinical intervention is defined as the action that 
identifies and prevents medication-related problems and 
optimizes patient’s medication therapy in cooperation with 
other health-care professionals.1 According to the American 
Society of Health-System Pharmacists (ASHP) position 
statement on pharmaceutical care, “The pharmacist is 
personally accountable for patient outcomes that ensue from 
the pharmacist’s actions and decisions. As an accountable 
member of the health-care team, the pharmacist must 
document the care provided.”2 Types of clinical interventions 
may vary, but each is patient specific. The most commonly 
documented interventions made by pharmacists involved in 
patient care include: appropriate medication selection, dosage 
and/or interval adjustment, initiation or discontinuation of drug 
therapy, elimination of therapeutic duplication, addressing 
untreated indication, pharmacokinetic monitoring, medication 
education, and drug-drug interactions.1,3   
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Team-based direct patient care has been identified as vital to 
meet patient needs and to improve health-care outcomes.4 
Furthermore, some studies concluded that coordinated care 
between physicians and pharmacists could  improve patient 
care outcomes.5-8 In the position paper from American College 
of Clinical Pharmacy task force on critical care pharmacy 
services, clinical pharmacists in critical care units (CCU) are 
recognized as essential members of physician-led 
multidisciplinary team for the delivery of quality care to 
critically ill patients.9 Brilli et al. stated the importance of having 
a multidisciplinary model wherein dedicated intensive care unit 
(ICU) personnel, specifically the intensivist, the ICU nurse, 
respiratory care practitioner, and pharmacist, all work as a 
team.10  Clinical pharmacists are trained to provide direct 
patient care and to monitor medication therapy with the goal 
of achieving desired therapeutic outcomes and reducing 
adverse health events. Clinical pharmacists in ICU also offer 
expertise in nutritional support, cardiorespiratory 
resuscitation, clinical research, and comprehensive critical 
care.9 
 
A meta-analysis of 298 studies in inpatient and outpatient 
pharmacy settings demonstrated that pharmacist-provided 
patient care resulted in positive clinical outcomes through 
enhanced disease management.11 Pharmacist-recommended 
interventions in a critical care setting decreased the rate of 
preventable adverse drug events (ADEs) by 66%.12 A 70% 
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reduction of preventable adverse drug events have been 
reported when pharmacists participated in the hospital 
rounding team.13 Few studies have focused on the economic 
benefit of clinical pharmacist interventions in a critical care 
setting. Kopp et al. evaluated clinical interventions of a critical 
care pharmacist in a surgical intensive care unit over four and 
half months.14 Of 129 total clinical interventions, a positive 
economic outcome due to potential cost avoidance ranged 
between $205,919 and $280,421. Possible  cost avoidance was 
estimated based on the following formula: probability of 
adverse drug events x $6,395 x number of interventions.14 Kopp 
et al. calculated $6,395 by inflating $4,685, original value 
reported in the Bate’s article in 1997, using Consumer Price 
Index for the cost of preventable ADE.14 The authors of this 
study also identified chart review and medical rounds as two 
major clinical activities that are associated with the highest 
number of interventions and the greatest potential for cost 
avoidance.  
 
In 2013, American Society of Health-System Pharmacists 
conducted a national survey which focused on pharmacy 
practice in hospital setting in the United States. The results 
showed that the majority (83.9%) of hospitals collected 
information about type, frequency, and acceptance of 
interventions. However, less than half of surveyed hospitals 
analyzed the data for cost savings (49.6%). Also, the study did 
not focus on the critical care setting in hospitals located in rural 
areas. Less than one-third of hospitals (127 out of 414, 30.7%) 
in the survey were located outside of the metropolitan 
statistical area.15  
 
Despite 90% of the United States land mass being rural and 20% 
of Americans living in rural areas, only 12% of pharmacists 
practice in rural locations, indicating the need to address the 
shortage of clinical pharmacy services in the rural areas.16  
 
White County Medical Center/Unity Health is the 438-bed 
community hospital providing service to six-county rural areas 
in Arkansas. Before our study, the hospital did not offer any 
clinical pharmacy services. Over a period of time, new clinical 
pharmacy service was successfully implemented in the critical 
care unit. The purpose of our study was to assess physician 
acceptance rate of pharmacist-recommended interventions in 
the critical care unit at White County Medical Center/Unity 
Health in Arkansas, during the 5-year period following 
implementation of a new clinical pharmacist service, and to 
evaluate economic benefit of accepted pharmacist-
recommended selected interventions over one-year duration. 
 
METHODS 
Setting 
Harding University College of Pharmacy (HUCOP) collaborated 
with White County Medical Center/Unity Health to establish 
new clinical pharmacy service in the critical care unit. Before 
August 2008, the hospital had centralized pharmacy drug 
distribution; however, clinical pharmacy services did not exist. 
A faculty preceptor, who is a licensed pharmacist, initiated 
clinical interventions/services to improve patient care by 
communicating mostly in writing and occasionally verbally with 
physicians. Documented interventions from August 1, 2008, to 
December 31, 2013, were de-identified and included in this 
study. The study was approved by the Harding University 
Institutional Review Board (IRB) for Human Subjects and by the 
White County Medical Center/Unity Health Physician Review 
Committee.  
 
Data Collection 
During the study period, one HUCOP faculty member dedicated 
to the unit provided clinical recommendation to CCU 
physicians. Also, under the preceptor’s direct supervision, 
fourth-year students on advanced pharmacy practice 
experience (APPE) in the CCU provided recommendations. 
During the first five years of faculty collaboration with the CCU, 
the hospital did not have a rounding team. Therefore, the 
pharmacist communicated the majority of recommendations to 
physicians in a written format via designated form placed in 
patient charts. For urgent interventions, the pharmacist 
communicated with physicians by contacting via telephone or 
in person. Due to a software change in June 2011, interventions 
were electronically documented by the pharmacist using two 
separate software systems, initially CPSI hospital system and 
later MedMined program. Documented interventions in each 
system were evaluated by the same methodology and were 
recorded and reported together in this study.  
 
Data Analysis 
Review and analysis of intervention records began in January 
2013 and concluded in July 2014. To identify pre-existing 
classification system for drug related problems (DRP) and 
pharmacist intervention categories, a literature search was 
conducted in PubMed using the following search terms: “drug 
related problem classification systems” and “pharmacist 
intervention classification systems”. Selected classification 
systems from the literature search include: American Society of 
Hospital Pharmacists (ASHP) classification, national 
coordinating council for medication error reporting and 
prevention (NCC-MERP) taxonomy of medication errors, 
Westerlund system, and Pharmaceutical Care Network Europe 
(PCNE) system.17-20 After review of these classification systems, 
interventions performed in the CCU were assigned into the 
following eight categories: toxicity/adverse drug reactions 
(ADRs), education, monitoring, drug selection, undertreated, 
over or underdose, compliance with hospital protocols, and not 
classifiable. ‘Not classifiable’ category included interventions 
which did not fit into other seven categories. Each intervention 
was classified by the type and then further defined as accepted 
or rejected by the treating physician. Pharmacist-
recommended interventions implemented by the physician 
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within 72 hours were defined as accepted interventions. Both 
electronic and paper medical records were evaluated to 
determine if a recommendation was accepted.  
 
Evaluation of the potential cost saving and cost avoidance was 
performed by analyzing interventions between January 1, 2013, 
and December 31, 2013, the year with the highest acceptance 
rate. Cost saving is defined as the difference between the cost 
of the initial therapy and the new therapy.21,22 Amount of cost 
saving was calculated based on average wholesale price (AWP) 
obtained from Lexicomp and Micromedex for each medication 
that was discontinued or when a dose reduction was 
recommended.  
 
Cost avoidance is defined as prevention of additional medical 
resources utilization and drug misadventures/medication 
errors. 21,22 Potential cost avoidance associated with pharmacist 
interventions was calculated by using evidence based 
information in the medical literature (Table 4).23-30 Similar to 
our study, several other studies evaluated medical literature to 
calculate cost avoidance per intervention. For example, 
Campbell et al. conducted a comprehensive MEDLINE search to 
identify several studies which evaluated cost avoidance for 
different types of clinical pharmacy interventions.31 Each study 
was reviewed to establish an average cost avoidance value for 
the types of clinical interventions performed. Similar method 
was used in the study by Shepler et al., in which cost saving and 
cost avoidance were calculated using the primary and tertiary 
literature sources.23,31  
 
A literature search was conducted in PubMed and International 
Pharmaceutical Abstracts (IPA) databases from 2008 to 2014 
using the following search terms: “cost of rhabdomyolysis 
management”, “cost of methicillin-resistant Staphylococcus 
aureus management”, “cost saving associated with prevention 
of allergic reaction”, “cost of hyperglycemia management”, 
“cost of gastrointestinal bleeding management”, “cost of deep 
venous thrombosis management”, “cost of sepsis 
management”, and “cost of enoxaparin associated bleeding”. 
Using the methodology adopted from Campbell’s study, we 
used literature findings to estimate the cost avoidance for the 
selected types of interventions.  
 
To estimate cost avoidance for accepted interventions for 
which either medical references and/or cost avoidance values 
were not available, the modified method adopted from the 
studies by Saokaew and Nesbit was used.32,33 For each 
pharmacist intervention lacking cost avoidance reference, an 
intervention was evaluated to estimate the probability of a 
preventable adverse event (ADE) occurring on the basis of the 
clinical details surrounding the intervention. During this 
process, judgment based on patient's clinical data was used to 
assign each intervention into one of the five probability 
categories. The probability of a preventable ADE in the absence 
of intervention was set as: (1) 0 (zero; e.g. information 
requested), (2) 0.01 (very low; for problem orders such as 
clarifications, missing information, nonexistent strengths), (3) 
0.1 (low; for prevented a potentially significant reaction such as 
2-4 x normal dose, medication/dose inadequate to produce 
therapeutic effect; incorrect schedule/route with potential for 
therapeutic failure/toxicity; duplicate therapy with potential 
for additive toxicity), (4) 0.4 (medium; for prevented a 
potentially serious reaction e.g. allergy to drug ordered, no 
allergy information, 4-10 x normal dose; no adjustment of 
medication with renal failure or other issues such as 
hyperkalemia or elevated trough level), (5) 0.6 (high; for 
prevented a potentially fatal or severe reaction e.g. 10 x normal 
dose; narrow therapeutic range; life-threatening 
reaction/anaphylaxis).32 To calculate the average cost of an 
ADE, the average cost of a preventable adverse event reported 
in Bate’s study ($4,685) was inflated using the Consumer Price 
Index (CPI) from 2008 to 2013.33,34,35 Then, the average cost of 
an ADE was $7108.16 to $7561.18.  Lastly, cost avoidance for 
each intervention was calculated by multiplying the estimated 
probability of an ADE in the absence of the intervention with 
the average cost of an ADE. For example, a patient was 
receiving higher than indicated dose of vancomycin and had 
elevated vancomycin trough above 20. In this case, the 
pharmacist recommended to hold vancomycin dose for a 
patient until the vancomycin trough level dropped below 20. 
The pharmacist estimated the probability of an ADE, in the 
absence of the intervention, to be (4) 0.4 (medium). Therefore, 
the cost avoidance in this case was: 0.4 (probability of a 
preventable ADE ) × $7108.16 to $7561.18 (inflated average 
cost of a preventable adverse event) = $2843.20 to $3024.40 
This method was used to estimate cost avoidance for 91 
accepted interventions that lacked medical references and/or 
cost avoidance value in the literature.   
 
Statistical Analysis 
Descriptive analysis was carried out by Excel 2013. A descriptive 
analysis of documented interventions was performed to 
evaluate the acceptance rate of pharmacist interventions by 
physicians to sort out accepted interventions by category, and 
to conduct cost analysis of accepted interventions in 2013. 
Statistical analysis was carried out by GraphPad Prism 7. 
Fisher’s exact test was used to compare acceptance rate 
between each year and 2013, the year with the highest 
acceptance rate.  
 
RESULTS 
One thousand two hundred and seventy-five interventions 
were documented for the study period. The number of 
interventions varied each year. The lowest number of 
interventions was recorded in 2008; the highest number of 
interventions was documented in 2009. In 2008, the year when 
the clinical pharmacy service was initiated in the critical care 
unit, interventions were recorded only between August 1 and 
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December 31 and thus resulted in the lowest number of 
interventions. The physician acceptance rate increased each 
year from the lowest acceptance rate in 2008 to the highest 
acceptance rate in 2013. Fisher’s exact test demonstrated that 
the acceptance rate in 2013 was statistically significantly higher 
for 2008, 2009, 2010, and 2012.  (Appendix 1) The overall 
acceptance rate for all documented interventions in the CCU for 
the study period was 56% (Table 1 & Figure 1).   
 
The toxicity/adverse drug reactions category had the highest 
total acceptance rate and the hospital protocol compliance 
category had the lowest overall acceptance rate (Table 2 & 
Figure 2). The three most common types of documented 
interventions were in the undertreated, drug selection, and 
over/underdose categories. The top three types of 
interventions accounted for 75% of all documented 
interventions. Among these three categories, interventions in 
the drug selection category had the highest acceptance rate 
(Table 2 & Figure 2). 
 
Potential cost saving and cost avoidance were estimated using 
75 out of 166 accepted interventions in 2013 (Table 1). Ten of 
these interventions were used to calculate both cost saving and 
cost avoidance (Table 3 & 4). Potential cost saving was based 
on the overall cost saving for each medication that was 
discontinued or resulted in dose reduction (Table 3). The total 
cost saving for the selected interventions in the CCU for the 
study period was $432 (Table 3).  Potential cost avoidance was 
based on the overall cost avoidance for selected interventions 
which potentially prevented unfavorable clinical events 
documented in medical literature (Table 4).18-25 Prevention of 
allergic reactions had the lowest cost avoidance, and sepsis or 
septic shock prevention had the highest cost avoidance (Table 
4). For the selected interventions with available medical 
references, the overall cost avoidance was $400,598-$412,225 
(Table 4). Potential cost avoidance for interventions where cost 
could not be found in the medical literature was calculated 
separately and amounted to $52,741.36-$56,102.62 (Table 5). 
Sum of the total cost avoidance in table 4 and the overall cost 
avoidance in table 5 was $453,339.36-$468,327.62. 
 
Discussion 
In our study, the overall acceptance rate by physicians (56%) 
falls within the range of the acceptance rate reported in the 
literature. Viktil’s study is a literature review which evaluated 
the effects of pharmacist interventions on drug-related 
problems and clinical outcomes and the acceptance rate by the 
prescriber. In that study, the prescriber acceptance rate in the 
hospital and community pharmacy settings ranged between 
41% to 98%. Prescriber acceptance rate in hospital setting was 
89%-98%.36 Although reported range in Viktil’s article is wide, 
this could be due to various factors affecting the acceptance 
rate of pharmacist-recommended interventions. For example, 
several studies reported pharmacists’ participation in hospital 
medical rounds as one of the factors that helped to increase 
acceptance rate. In 2007, Kopp et al. reported that 80% of 
accepted interventions made by a critical care pharmacist in the 
surgical ICU were made during patient care rounds and chart-
review activities rather than during pharmacist-entered 
physician orders into the computer.14 Pedersen et al. reported 
that the number of clinical pharmacists attending medical 
rounds was 30.4% in 2001 and increased to 51.9% in 2013. 15, 37 
Although the overall percentage of pharmacists attending 
rounds with physicians is low, the percentage is higher in 
intensive care units. In 2004, MacLaren et al. evaluated clinical 
pharmacy services in ICUs via survey to the pharmacy directors. 
Responders reported that in their institutions, 62.2% of ICUs 
provided direct clinical pharmacy activities and pharmacists 
involved in these activities attended rounds 4.4 ± 1.5 days per 
week.38 
 
Our study demonstrates an increase in the acceptance rate of 
pharmacist-initiated recommendations by physicians over the 
five-year period. Similar findings were reported in the study 
conducted by Packard et al. who reported an increase in the 
acceptance rate for interventions recommended by pharmacy 
students from 2008 to 2013.39 Acceptance rate in 2013 was 
statistically significantly higher for 2008, 2009, 2010, and 2012. 
Although acceptance rate in 2013 was not statistically 
significantly higher for 2011, this could be possibly due to 
smaller number of interventions in year 2011 with slightly 
higher acceptance rate than in previous years. Furthermore, p-
value for 2011 vs 2013 was 0.0528, which suggests that it 
almost reached statistical significance. 
 
Although there was a fewer number of recommended 
interventions in the toxicity/ADRs category, we hypothesize 
that the highest acceptance rate was due to the desire to 
enhance patient safety by avoiding significant adverse events. 
The acceptance rate in the toxicity/ADRs category is consistent 
with the results reported by Anderegg et al. study conducted in 
a tertiary hospital.40 Although the overall acceptance rate in 
compliance with hospital protocols category was low, annual 
acceptance rate in this category increased over the study 
period. Ongoing persistence on the part of the pharmacist in 
creating awareness of these protocols might have led to the 
yearly increase in acceptance rate. The undertreated category 
had the highest number of documented interventions. 
However, the rate of acceptance minimally increased over the 
study period. We concluded, similarly to Anderegg et al., that 
some of the pharmacist-recommended interventions in the 
CCU included medical conditions outside the primary reason for 
the admission and may be viewed by physicians as not being an 
immediate concern for the current admission.40 In 2006, 
Prosser et al. reported that hospital physicians prefer not to 
interfere with the prescription of the patient’s primary care 
physician when patients are hospitalized.41  
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Pharmacist interventions could potentially result in positive 
economic outcomes. Evaluation of cost saving and cost 
avoidance is essential to assess the economic benefit of a 
pharmacist’s clinical interventions. Kopp et al. reported that 
when a pharmacist in a surgical intensive care unit participated 
in medical rounds or chart review, approximately $80,000 to 
$110,000 of cost avoidance was reported in each activity and 
$160,000 to $220,000 of cost avoidance for both activities.14 A 
systematic review of 126 studies in inpatient (n=59) and 
outpatient (n=67) settings conducted by Chisholm-Burns et al. 
examined the economic effect of pharmacist-provided direct 
patient care on health outcomes in the United States. Among 
20 studies, the major economic benefit came from the 
decreased length of stay (LOS), lower drug cost, and avoidance 
of potential unfavorable clinical events. This study 
demonstrated that the economic benefit per patient ranged 
between $145 and $3,768.42  
 
As noted previously, decreased length of stay is one of the 
major factors contributing to the economic benefit of the 
pharmacist interventions. This fact suggests that the increased 
LOS due to ADE can significantly contribute to the economic 
loss for the hospital. For example, Bates et al. showed that 
preventable ADEs, which mostly occurs during ordering and 
administration stages, increase the average hospital stay by 2.2 
days with an associated total cost of $3,244.34  
 
The annual cost attributable to preventable ADEs for a 700-bed 
teaching hospital was estimated to be $2.8 million.34  Therefore, 
clinical pharmacists can play a major role in reducing the 
economic loss associated with increased LOS due to the 
preventable ADEs.  
 
Economic analysis of interventions or service outcomes 
requires a comprehensive measure of economic costs.42 
Although in our study analysis of pharmacist interventions for 
one year time period was performed, since economic gain was 
difficult to be quantified with certainty for some interventions 
either due to missing documented information or lack of 
supporting literature, evaluated clinical interventions had 
economic benefit by either drug cost reduction or potential 
prevention of adverse clinical events that could result in total 
increase in medical care cost. Cost avoidance was higher than 
cost saving. While cost saving only reflects price of medications, 
cost avoidance accounts for overall management of adverse 
clinical outcomes. However, since the year with the highest 
acceptance rate was selected to evaluate economic benefit, it 
might introduce bias.  
 
Complete assessment of economic benefit associated with 
pharmacist interventions should also take into consideration 
the cost associated with hiring a clinical pharmacist. In this 
study, there was no expenditure to the medical institution 
associated with hiring a clinical pharmacist since the 
pharmacist’s salary and benefits were paid by an academic 
institution. Furthermore, the amount of time spent by the 
pharmacist to implement new clinical service was not 
documented. As a result, the pharmacist’s salary, time, and the 
benefit versus cost ratio were not included in our study for the 
cost analysis. At other institutions, the expense associated with 
implementing a new clinical pharmacy service could be offset 
by economic savings obtained through pharmacist’s 
interventions. For example, in a systematic review which 
evaluated economic benefit of clinical pharmacy service from 
fifty-nine studies between 1996 and 2000, Schumock et al. 
reported benefit versus cost ratio to be 4:1, a hospital saving up 
to $4 for every $1 invested in clinical pharmacy.43 In another 
systemic review from three studies between 2006 and 2010, 
Touchette et al. reported benefit versus cost ratio ranges from 
1.05:1 to 25.95:1, a hospital saving ranges as little as $1.05 to 
$25.95 for every $1 invested in clinical pharmacy.44 The broad 
range of the benefit versus cost ratio can be due to a number 
of clinical pharmacists required per institution, the pharmacist 
hiring salary, and pharmacist time spent on interventions might 
vary in each institution.  
 
The study described here is unique since it evaluated 
interventions made by a single clinical pharmacist from the 
beginning of their service in the critical care unit. Furthermore, 
this study is distinctive as one of few studies which analyzed the 
acceptance rate and cost saving of the pharmacist interventions 
in the critical care setting in the rural hospital.  
 
No precise measure of the collaborative relationship between 
the clinical pharmacist and physicians was completed.  
However, increase in the accepted interventions from 2008-
2013 suggests that the development and maturation of the 
interprofessional relationships helped to improve the 
acceptance rate of the pharmacist interventions.   
 
Our study has a number of limitations. Our study was 
conducted in the critical care unit, and therefore interventions 
may vary in other types of intensive care units. Also, due to the 
retrospective nature of the study, response by physicians could 
have occurred with or without the written recommendation by 
the pharmacist. Also, the analysis of economic benefit for 
selected interventions within a one year time instead of the 
five-year time frame was completed. The overall cost saving 
and cost avoidance would probably be higher if all interventions 
over 5 year study period were accounted in this analysis. 
Furthermore, since an external reviewer did not independently 
evaluate economic benefit, there is a chance for overinflated 
costs. Another limitation of our study is the use of the modified 
method for analyzing cost avoidance for the pharmacist 
interventions that lack literature references. In Saokawe and 
Nesbit’s studies, a panel which consisted of several clinical 
pharmacists was used to assign the probability of preventable 
ADE for each pharmacist intervention. In our study, only one 
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clinical pharmacist was available at the time of this project and 
the likelihood of preventable ADE was assigned by a research 
student after completion of data collection and during data 
analysis to minimize the investigator bias. It is possible that the 
probability of preventable ADE for the pharmacist interventions 
calculated in this study may differ from the probability of 
preventable ADE if it was calculated by the panel of clinical 
pharmacists.  
 
Another limitation of our study is a lack of assessment of 
collaboration between a physician and a pharmacist and how it 
impacted physician acceptance rate. In the future, a Physician-
Pharmacist Collaboration Instrument (PPCI) could be utilized to 
measure a degree of physician-pharmacist collaboration and its 
impact on the acceptance of interventions.5 Lastly, the major 
limitation of our study is mostly using descriptive analysis with 
minimal statistical analysis of found data. Prior to initiation of 
new clinical pharmacy service in the CCU, pharmacist 
interventions and the amount of time spent for each 
pharmacist intervention was not documented. If this data was 
available, several statistical analysis such as the student’s 
unpaired t-test and benefit versus cost ratio could be 
conducted to assess whether the implementation of the new 
clinical pharmacy service significantly increased overall number 
of the pharmacist’s interventions and acceptance rate by 
physicians, and cost saving to the institution. However, there 
are some descriptive publications focusing on pharmacist 
interventions; one such study is by Olson et al.45  
 
CONCLUSION 
This study differs from currently available literature on clinical 
pharmacist interventions in that it analyzed the acceptance rate 
and cost-benefit of the pharmacist interventions in the critical 
care setting in the rural hospital. Physician acceptance rate of 
pharmacist-recommended interventions in the critical care unit 
at White County Medical Center/Unity Health in Arkansas 
gradually increased over the 5-year period following 
implementation of a new clinical pharmacist service. 
Pharmacist’s ongoing effort in building rapport with the CCU 
nursing director, nursing personnel, and physicians at WCMC 
might have helped to promote the implementation of the 
recommendations. Furthermore, clinical pharmacist expertise 
in managing drug regimens for the patients to minimize 
preventable ADEs might enable to support and guide the 
interdisciplinary team in delivering optimal therapeutic patient 
care. A one-year analysis of potential cost saving and cost 
avoidance of pharmacist interventions demonstrated a positive 
economic outcome based on current medical cost. This can be 
attractive to a health-system organization and may help to 
justify the cost of hiring a clinical pharmacist. Clinical 
pharmacist interventions may improve patient outcomes and 
provide potential economic benefit for the institution. 
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Table 1 & Figure 1.  
Number of Recommended Interventions and Acceptance Percentage by Year 
 
Year Number of Accepted Interventions/Total Number of Interventions 
(Percentage of Accepted Interventions) 
2008 40/97 (41%) 
2009 158/349 (45%) 
2010 91/174 (52%) 
2011 86/141 (61%) 
2012 176/281 (63%) 
2013 166/233 (71%) 
Total 717/1275 (56%) 
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Table 2 & Figure 2.  
Types of Accepted Interventions by Category and Yeara 
 
Category 
Accepted/Total Number of Interventions by Year  
(% of Acceptance) Accepted/Total Number of 
Interventions Over Study 
Period  
(% of Acceptance) 
2008 
n (%) 
2009 
n (%) 
2010 
n (%) 
2011 
n (%) 
2012 
n (%) 
2013 
n (%) 
Toxicity/ADRsa 0 (NA) 2/2 (100) 0 (NA) 0 (NA) 1/1 
(100) 
2/2 
(100) 
5/5 (100) 
Education 0 (NA) 6/6 (100) 5/5 
(100) 
4/5 (80) 3/3 
(100) 
0 (NA) 18/19 (95) 
Monitoring 3/8 (38) 14/22 
(64) 
5/10 
(50) 
6/8 (75) 12/15 
(80) 
18/23 
(78) 
58/86 (67) 
Not Classifiableb 3/9 (33) 5/8 (63) 3/8 (38) 3/3 
(100) 
3/4 (75) 7/7 
(100) 
24/39 (62) 
Drug Selection 3/9 (33) 30/69 
(43) 
8/13 
(62) 
20/35 
(57) 
52/82 
(63) 
65/82 
(79)  
178/290 (61) 
Undertreated 25/44 
(57) 
62/113 
(55) 
41/73 
(56) 
23/39 
(59) 
50/84 
(60) 
22/39 
(56) 
223/392 (57) 
Over or Underdose 2/8 (25) 22/66 
(33) 
22/37 
(59) 
25/43 
(58) 
45/74 
(61) 
28/50 
(56) 
144/278 (52) 
Compliance with 
hospital protocols 
4/19 
(21) 
17/63 
(27) 
7/28 
(25) 
5/8 (63) 10/18 
(56) 
24/30 
(80) 
67/166 (40) 
 
aADRs = Adverse Drug Reactions 
bNot Classifiable = Interventions that do not fall into any of the following categories: drug selection, over or underdose, monitoring, 
compliance with hospital protocols, undertreated, education, toxicity/adverse drug reactions 
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Table 3.  
Outcome Measure Examples of Cost Reduction per Daily Dose for 2013a 
 
Selected Examples of Interventions Number of Accepted 
Interventions 
Estimated Cost 
Savingb,c 
Discontinue famotidine 20 mg intravenously BID for patients who are 
on pantoprazole  
10 $29 
Discontinue azithromycin 500 mg intravenously for patients who are 
on levofloxacin   
4 $29 
Change enoxaparin 40 mg subcutaneously QD to 30 mg 
subcutaneously QD for DVT prophylaxis due to decline in renal 
function 
5 $33 
Discontinue enoxaparin 40 mg subcutaneously QD in patients with 
low platelet count  
6 $158 
Discontinue ceftriaxone 2 g intravenously BID in a patient on 
piperacillin/tazobactam 
1 $183 
Total cost saving for accepted interventions 26* $432 
 
aBID = twice daily, QD = once daily, DVT = deep venous thrombosis 
bDrug cost saving per dose is based on average wholesale price (AWP) 
cTotal cost saving =  drug cost saving per dose x number of accepted interventions  
*10 of these interventions were used to calculate both cost saving and cost avoidance 
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Table 4.  
Estimated Cost Avoidance Examples for Prevention of Potential Adverse Clinical Outcomes for 2013a 
Selected Examples of 
Interventions 
Clinical Rationale 
for 
Recommendation 
Literature Source Used 
for Cost Avoidance 
Calculations  
Number of 
Accepted 
Interventions 
Estimated Cost 
Avoidance 
(Cost 
avoidance per 
intervention) b,c 
Update patients' 
allergies record 
Prevent allergic 
reaction 
23. Shepler BM. Cost 
savings associated with 
pharmacy student 
interventions during 
APPEs. Am J Pharm 
Educ. 2014; 78(4):71. 
8 $8,720 ($1,090) 
Change simvastatin 80 
mg by mouth QD to 20 
mg by mouth QD in a 
patient on amiodarone 
Prevent 
rhabdomyolysis 
24. Lazar LD, Pletcher 
MJ, Coxson PG et al. 
Cost-effectiveness of 
statin therapy for 
primary prevention in a 
low-cost statin era. 
Circulation. 2011; 
124(2):146-53. 
1 $11,745 ($11,745) 
Compliance with nasal 
MRSA colonization 
screening for newly 
admitted patients 
Prevent MRSA 
spread 
25. Kang J, Mandsager P, 
Biddle AK, Weber DJ et 
al. Cost-effectiveness 
analysis of active 
surveillance screening 
for MRSA in an 
academic hospital 
setting. Infect Control 
Hosp Epidemiol. 2012; 
33(5):477-86. 
2 $29,910 ($14,955) 
Blood glucose 
management to 
maintain it between 
140-180 mg/dL 
AACE and ADA 
recommendation 
for critically ill 
patients in order 
to reduce LOS in 
ICU and improve 
management of 
infection 
26. Gillinov AM, Shi W, 
Rosen A et al. Cost of 
postoperative 
hyperglycemia in cardiac 
surgery patients. J Am 
Coll Cardiol. 2014; 
63(12_S). 
13 $34,177 ($2,629)  
Initiate stress ulcer 
prophylaxis in patients 
on mechanical 
ventilation 
Prevent 
gastrointestinal 
bleeding 
27. Gerson L. Cost-
effectiveness analysis of 
management strategies 
for obscure GI bleeding. 
Gastrointest Endosc. 
2008; 68:920-36. 
3 $40,956 ($13,652) 
Initiate/adjust dose for 
pharmacological DVT 
prophylaxis and/or 
initiate mechanical DVT 
prophylaxis 
Prevent DVT 28. Patel R, Badger N. 
The Impact of a 
pharmacist's 
participation on 
hospitalists' rounds. 
Hosp Pharm. 2010; 
45(2):129-34. 
11 $66,000 ($6,000) 
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Modify antimicrobial 
therapy to include 
coverage for MDR 
pathogens in patients 
with infection and 
declining clinical status 
Prevent sepsis 
and/or septic 
shock 
29. Elixhauser A. 
(Agency for Healthcare 
Research and Quality), 
Friedman B. (Agency for 
Healthcare Research 
and Quality), Stranges E. 
(Thomson Reuters). 
Septicemia in U.S. 
Hospitals, 2009. HCUP 
Statistical Brief #122. 
Agency for Healthcare 
Research and Quality, 
Rockville, MD. 2011; 
http://www.hcup-
us.ahrq.gov/reports/stat
briefs/sb122.pdf 
10 $185,000 ($18,500) 
Discontinue enoxaparin 
in patients with 
consistently decreasing 
platelet count or adjust 
enoxaparin dose in 
patients with renal 
insufficiency 
Reduce risk of 
bleeding 
30. Saokaew S, 
Khaisombat N, 
Chaiyakunapruk N et al. 
Attributable cost and 
length of stay for 
patients with 
enoxaparin-associated 
bleeding. Value Health 
Reg Iss. 2012; 1:41-5. 
11 $24,090-$35,717d 
($2,190-$3,247) 
Total cost  - - 59* $400,598-$412,225d 
 
aQD = once daily, MRSA = methicillin-resistant Staphylococcus aureus, AACE = American Association of Clinical 
Endocrinologists, ADA = American Diabetes Association, LOS = length of stay, ICU = intensive care unit, DVT = deep venous 
thrombosis, MDR = multi-drug resistant 
bCost avoidance is based on the literature source 
cTotal cost avoidance = cost avoidance for preventing clinical event per case x number of accepted interventions 
dRange indicates cost for minor vs major bleeding 
*10 of these interventions were used to calculate both cost saving and cost avoidance.   
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Table 5.  
Pharmacist Interventions Lacking Cost Avoidance Medical References 
 
Category Probability of preventable 
Adverse Drug Events (ADE) 
(Range: 0 to 1) 
Total Number of 
Accepted 
Interventions 
Calculated Total Cost 
Avoidance Range  
Duplicate therapy 0.1 (Duplicate therapy) 30 $21,324 to $22,683 
Over or Underdose and 
Undertreated 
0.1 (Medication/dose 
inadequate to produce 
therapeutic effect or 
incorrect schedule/route 
with potential for 
therapeutic 
failure/toxicity) 
26 $18,480.8 to $19,658.6 
Compliance/Drug Selection  
 
0.01 (clarifications, 
missing information) 
12 $852.96 to $907.32 
 
0.1 (Medication/dose 
inadequate to produce 
therapeutic effect) 
 
5 $3,554 to $3,780.5 
 
0.4 (no adjustment of 
medication with renal 
failure or other issues such 
as hyperkalemia or 
elevated trough level) 
3 $8,529.6 to $9,073.2 
 
Monitoring N/Aa 15 N/Aa 
Total - - $52,741.36 to $56,102.62  
 
 
aN/A = Not Applicable (e.g., Pharmacist request to continuously monitor aPTT after heparin administration. In this case, 
patient may or may not have ADE and therefore, probability of ADE cannot be calculated) 
Preventable ADE cost is $4685 (Study period from Feb 1993 to July 1993 for Bates study), Preventable ADE cost after 
multiplying with Consumer Price Index (CPI) in August 2008 to December 2013 (5 Year Study Period): 
August 2008: $4685 (July 1993) x CPI = $7108.16 ~ $7108  
December 2013: $4685 (July 1993) x CPI = $7561.18 ~$7561 
(e.g., Total # of interventions X the probability of ADE X the average cost of preventable ADE = 30 X 0.1 X 7108 or 7561 = 
$21324 to $22683) 
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Appendix 1. Statistical Analysis of Acceptance Rate Over Study Period 
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